Lakatos J, Molnár M, Tóth K
II.nd Department of Internal Medicine, University Medical School Pécs, Hungary.
Acta Physiol Hung. 1996;84(4):433-5.
The authors report the results of an open clinical study using 400 mg Bezafibrate once a day. Among 25 diabetic patients (type II.) underwent a 4 weeks period with nutritional advice. Average changes from inclusion levels were -24% for total cholesterol, -56% for triglicerides, +11.9% for HDL-cholesterol, -19% for plama fibrinogen. In conclusion, bezafibrate at a daily dose of 400 mg had significant lipid-modifying properties but also exhibited a beneficial effect on other related risk factors such as fibrinogen reduction.
作者报告了一项开放临床研究的结果，该研究使用每天一次400毫克的苯扎贝特。25名II型糖尿病患者在接受了为期4周的营养建议。与纳入水平相比，总胆固醇平均变化为-24%，甘油三酯为-56%，高密度脂蛋白胆固醇为+11.9%，血浆纤维蛋白原为-19%。总之，每日剂量400毫克的苯扎贝特具有显著的调脂特性，而且对其他相关危险因素如降低纤维蛋白原也有有益作用。
